We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| RayzeBio Inc | NASDAQ:RYZB | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 62.49 | 60.00 | 68.11 | 0 | 01:00:00 |
From Jul 2023 to Jul 2024
By Colin Kellaher
RayzeBio shares nearly doubled in premarket trading Tuesday after the clinical-stage radiopharmaceutical therapeutics company agreed to be acquired by Bristol Myers Squibb at a rich premium.
Bristol Myers will pay $62.50 a share for RayzeBio, a 104% premium to Friday's closing price of $30.57.
The deal carries an equity value of around $4.1 billion and a total value of $3.6 billion net of RayzeBio's cash on hand.
RayzeBio shares were recently up 99% to $60.90 in premarket trading.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
December 26, 2023 07:49 ET (12:49 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year RayzeBio Chart |
1 Month RayzeBio Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
